TCGA-E2-A1B0-01A-11R-A12P-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 54
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.480
- E2F_TARGETS+0.470
- MTORC1_SIGNALING+0.440
- MYC_TARGETS_V2+0.420
- G2M_CHECKPOINT+0.410
- MITOTIC_SPINDLE+0.410
- TGF_BETA_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- ANDROGEN_RESPONSE+0.370
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- ESTROGEN_RESPONSE_EARLY-0.250
- ESTROGEN_RESPONSE_LATE-0.240
- DNA_REPAIR-0.180
- KRAS_SIGNALING_DN-0.080
- P53_PATHWAY-0.060
- UV_RESPONSE_UP-0.030
- INTERFERON_GAMMA_RESPONSE-0.020
- BILE_ACID_METABOLISM-0.010
- MYOGENESIS-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.872 |
| 2 | TCGA-BH-A1FU-01A-11R-A14D-07 | — | C | 0.857 |
| 3 | SAMN03290908 | — | — | 0.851 |
| 4 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.827 |
| 5 | R275 | — | — | 0.826 |
| 6 | TCGA-66-2734-01A-01R-0980-07 | — | cohortSQ1 | 0.822 |
| 7 | TCGA-ZF-AA4N-01A-11R-A38B-07 | — | — | 0.822 |
| 8 | TCGA-C8-A135-01A-11R-A115-07 | — | C | 0.821 |
| 9 | MNG308 | — | — | 0.811 |
| 10 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.480 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |